Arkolith/Insider Trading/KNSA/Form 4

Megna Michael R

CHIEF ACCOUNTING OFFICERKiniksa Pharmaceuticals International, plc (KNSA) · full profile →Form 4 · filed Oct 22, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2.0M
Net Open-Market Flow
-$2.0M
Transactions
12
7 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 20, 2025Option exercise(M)791$15.50$12K39K
Oct 20, 2025Option exercise(M)6K$12.97$80K45K
Oct 20, 2025Option exercise(M)10K$11.10$109K55K
Oct 20, 2025Option exercise(M)10K$11.97$118K65K
Oct 20, 2025Option exercise(M)13K$10.76$138K78K
Oct 20, 2025Sell(S)37K$38.72$1.4M40K
Oct 20, 2025Sell(S)13K$39.31$520K27K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 20, 2025Option exercise(M)791—$00
Oct 20, 2025Option exercise(M)6K—$00
Oct 20, 2025Option exercise(M)10K—$00
Oct 20, 2025Option exercise(M)10K—$00
Oct 20, 2025Option exercise(M)13K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001464583-25-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML